Bcr-Abl(Bcr-Abl酪氨酸激酶)
Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).
- Cat.No. 产品名称 Information
-
GC25669
Nilotinib hydrochloride
Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
-
GC65592
SNIPER(ABL)-020
-
GC64462
Asciminib hydrochloride
An allosteric inhibitor of Abl1
-
GC63332
S116836
-
GC62453
GZD856 formic
-
GC62207
Olverembatinib
A Bcr/Abl inhibitor
-
GC62103
Vodobatinib
Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.
-
GC60930
Imatinib D4
-
GC39612
Imatinib D8
-
GC45828
Ponatinib-d8
An internal standard for the quantification of ponatinib
-
GC36807
ON 146040
-
GC36167
GMB-475
GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.
-
GC35897
DPH
-
GC35812
Dasatinib hydrochloride
An inhibitor of Abl and Src
-
GC35753
CT-721
-
GC35682
CHMFL-ABL/KIT-155
-
GC35651
Cenisertib
-
GC35462
Bafetinib
A Bcr-Abl inhibitor
-
GC40080
Bosutinib-d8
An internal standard for the quantification of bosutinib
-
GC33368
BCR-ABL-IN-2
-
GC33351
CZC-8004 (CZC-00008004)
A tyrosine kinase inhibitor
-
GC33343
BCR-ABL-IN-1
-
GC33201
GZD856
-
GC32867
Flumatinib (HHGV678)
A Bcr-Abl inhibitor
-
GC32703
Asciminib (ABL001)
An allosteric inhibitor of Abl1
-
GC10607
GNF-7
A multi-kinase inhibitor
-
GC15884
Dasatinib Monohydrate
An inhibitor of Abl and Src
-
GC11140
Radotinib(IY-5511)
A selective Bcr-Abl tyrosine kinase inhibitor
-
GC10314
Imatinib (STI571)
伊马替尼 (STI571) (STI571) 是一种口服生物可利用的酪氨酸激酶抑制剂,可选择性抑制 BCR/ABL、v-Abl、PDGFR 和 c-kit 激酶活性。伊马替尼 (STI571) (STI571) 通过在 ATP 结合位点附近结合而起作用,将其锁定在封闭或自我抑制的构象中,从而半竞争性地抑制蛋白质的酶活性。伊马替尼 (STI571) 也是 SARS-CoV 和 MERS-CoV 的抑制剂。
-
GC14007
DCC-2036 (Rebastinib)
An orally bioavailable tyrosine kinase inhibitor
-
GC10915
GZD824
A Bcr/Abl inhibitor
-
GC13592
PD173955
A tyrosine kinase inhibitor
-
GC13914
Flumatinib mesylate
A Bcr-Abl inhibitor
-
GC12779
PPY A
PPY A 是一种有效的 T315I 突变体和野生型 Abl 激酶抑制剂,IC50 分别为 9 和 20 nM。 PPY A 抑制用野生型 Abl 和 Abl T315I 突变体转化的 Ba⁄F3 细胞,IC50 分别为 390 和 180 nM。 PPY A可用于慢性粒细胞白血病(CML)的研究。
-
GC12637
PD 180970
An inhibitor of Bcr-Abl
-
GC12172
1-Naphthyl PP1
Inhibitor of modified ‘analog-sensitive’ kinases
-
GC15079
GNF 5
An allosteric inhibitor of Bcr-Abl
-
GC10858
GNF 2
An allosteric inhibitor of Bcr-Abl
-
GC15579
Adaphostin
Adaphostin (NSC 680410) 是 AG957 的金刚烷基酯,是一种有效的 p210bcr/abl 抑制剂 (IC50=14 μM)。 Adaphostin 在人 T 淋巴细胞白血病细胞系中诱导细胞凋亡(IC50 范围为 17 至 216 nM)。 Adaphostin 对慢性和急性髓性白血病细胞具有显着的选择性活性。 Adaphostin 增加了 CLL B 细胞内的活性氧 (ROS) 水平。
-
GC14075
Nocodazole
A microtubule altering agent
-
GC10970
WP1130
A deubiquitinase inhibitor
-
GC14396
Ponatinib (AP24534)
An inhibitor of native and mutant Bcr-Abl
-
GC15197
Saracatinib (AZD0530)
A dual inhibitor of c-Src and Abl
-
GC11759
Imatinib Mesylate (STI571)
An inhibitor of c-Abl, Bcr-Abl, PDGFR, and c-Kit
-
GC13343
Bosutinib (SKI-606)
An inhibitor of Src and Abl kinases
-
GC14129
Nilotinib(AMN-107)
A Bcr-Abl inhibitor
-
GC13102
XL228
A tyrosine kinase inhibitor
-
GC14237
Nilotinib monohydrochloride monohydrate
A Bcr-Abl inhibitor
-
GC10914
AST 487
A multi-kinase inhibitor
-
GC14592
KW 2449
A multi-kinase inhibitor